Animal Biotechnology Market by Product Type (Recombinant Proteins, Vaccines), Technology (Cell Culture, Genetic Engineering, PCR And DNA Sequencing), Application, End-User - Global Forecast 2025-2032
Description
The Animal Biotechnology Market was valued at USD 31.04 billion in 2024 and is projected to grow to USD 33.81 billion in 2025, with a CAGR of 8.71%, reaching USD 60.56 billion by 2032.
Overview of Animal Biotechnology Advancements and Market Dynamics Shaping the Future of Veterinary Health and Agriculture
Animal biotechnology represents a convergence of molecular science, genetic engineering, and veterinary research, delivering innovative solutions that improve animal health, productivity, and welfare. Over the past decade, breakthroughs in gene editing, cell culture platforms, and recombinant protein expression have redefined how the industry approaches diagnostics, therapeutics, and nutritional supplements for livestock, companion animals, and aquaculture. These advances have not only accelerated the development of safer and more effective vaccines but also enabled precise interventions in metabolic pathways to enhance growth performance and disease resistance.
In this context of rapid transformation, stakeholders face an unprecedented need for comprehensive market intelligence that illuminates technological progress, regulatory landscapes, and competitive strategies. As emerging players introduce next-generation sequencing and transgenic models into their R&D pipelines, established firms are expanding contract research and manufacturing collaborations to maintain leadership. This introduction lays the groundwork for a detailed exploration of the structural shifts, tariff influences, segmentation patterns, regional dynamics, and strategic imperatives that define the modern animal biotechnology ecosystem.
Major Shifts Propelling Animal Biotechnology from Gene Editing Breakthroughs to Integrated Diagnostic Solutions in Veterinary and Livestock Management
Over recent years, animal biotechnology has undergone radical transformation driven by converging scientific disciplines and evolving stakeholder priorities. Initially centered on recombinant protein production and conventional vaccine design, the landscape now embraces precision gene editing tools such as CRISPR, high-throughput cell culture systems, and integrated diagnostic assays. Consequently, developers are shifting from monolithic product pipelines toward modular platforms that accommodate rapid customization, accelerated timelines, and adaptive regulatory strategies.
Moreover, the sector has witnessed a surge in partnerships between academic research institutions and private enterprises, fostering knowledge exchange and de-risked development pathways. Simultaneously, digital convergence through data-driven decision support and remote monitoring technologies is redefining veterinary health management. These transformative shifts underscore the importance of agility, cross-disciplinary collaboration, and forward-looking business models to capitalize on opportunities in preventive care, therapeutic innovation, and feed additive optimization.
Assessing the 2025 United States Tariffs Impact on Global Animal Biotechnology Trade Flows, Supply Chains, and Research Collaborations
The introduction of elevated US tariffs in 2025 has altered the calculus for global trade in animal biotechnology inputs and finished products. Raw materials such as enzyme substrates and cell culture reagents are now subject to additional duties, prompting many manufacturers to reassess sourcing strategies and inventory management practices. As a direct consequence, supply chain resilience has become a central concern, with companies exploring regionalized production hubs and multi-tiered logistics networks to mitigate exposure to tariff fluctuations.
In parallel, research collaborations spanning cross-border academic and industrial partners are adapting contractual frameworks to reflect shifting cost structures. Licensing agreements, joint ventures, and technology transfer arrangements now account for potential duty adjustments, ensuring that development timelines remain intact despite the evolving trade environment. Ultimately, these dynamics are reshaping procurement, partnership, and pricing strategies across the animal biotechnology value chain.
Comprehensive Analysis of Product Type, Technology, Application, and End-User Segments Driving Animal Biotechnology Market Development
A granular look at product type segmentation reveals that recombinant proteins and vaccines form the backbone of innovation. Within recombinant proteins, antibodies, enzymes, and growth hormones serve distinct roles in diagnostics, biocatalysis, and metabolic regulation. Delving deeper, enzymes such as lipases, phytases, and proteases enable targeted feed additive solutions that enhance nutrient absorption, while vaccine categories ranging from DNA to live attenuated and subunit formats cater to tailored immunization strategies.
Turning to technology, cell culture methodologies span avian, insect, and mammalian cell lines to support scalable biomanufacturing. Genetic engineering encompasses gene editing, synthesis, and transgenic approaches that underpin advanced therapeutic development. PCR and DNA sequencing technologies, including next-generation platforms, specialized kits, and traditional Sanger workflows, provide the analytical backbone for pathogen detection and genomic characterization. Application segmentation highlights diagnostics, drug discovery, and feed additives, each supported by specialized assay formats, optimization protocols, and performance metrics. Finally, end users from animal farms to contract research organizations, pharmaceutical manufacturers, and research laboratories demand customizable solutions that align with operational scale, regulatory compliance, and cost-effectiveness.
Strategic Regional Dynamics Defining Growth Patterns and Opportunities in Americas, Europe, Middle East & Africa, and Asia-Pacific Animal Biotechnology Markets
In the Americas, robust R&D infrastructure, established commercial supply chains, and proactive regulatory agencies drive high-value innovation in animal biotechnology. Domestic producers benefit from local access to advanced bioprocessing facilities and a mature venture capital ecosystem, enabling iterative product refinement and rapid scale-up. Meanwhile, cross-border collaborations within North and South America expand market reach and foster capacity building in emerging economies.
Across Europe, the Middle East & Africa region, harmonized regulatory frameworks, public funding initiatives, and pan-regional research consortia support harmonized development pathways. European Union directives on animal welfare and product registration shape the competitive landscape, whereas Middle East and African markets exhibit growing livestock production and immunization uptake. In the Asia-Pacific, surging demand for protein through intensified livestock farming, coupled with government incentives for biotechnology manufacturing, has catalyzed rapid expansion. Local players are investing in cell culture facilities and genomic services, while multinational firms forge strategic alliances to navigate diverse regulatory regimes.
Leading Industry Participants Shaping Competitive Dynamics and Collaborative Innovations within the Global Animal Biotechnology Landscape
Leading companies in the animal biotechnology space are orchestrating dynamic partnerships to bolster their pipelines and expand market presence. Established biopharmaceutical firms are integrating genomic editing capabilities and contract research expertise, while specialized startups are advancing proprietary platforms for vaccine antigen discovery and enzyme engineering. These actors frequently engage in licensing agreements, joint development projects, and co-manufacturing arrangements to optimize resource allocation and accelerate commercialization timelines.
Strategic acquisitions have also become a hallmark of competitive positioning, with larger entities targeting niche players to augment their product portfolios or secure novel technology platforms. Simultaneously, cross-sector collaborations with feed additive producers, diagnostic assay developers, and digital monitoring providers are emerging to create end-to-end solutions. Through these maneuvers, key industry participants are not only consolidating capabilities but also fostering ecosystems that facilitate continuous innovation and sustainable growth.
Strategic Recommendations for Industry Leaders to Enhance Resilience, Foster Innovation, and Capitalize on Emerging Animal Biotechnology Trends
Industry leaders should prioritize investment in flexible manufacturing platforms that can pivot swiftly to new product candidates or capacity expansions. By adopting modular bioprocessing designs and cloud-enabled analytics, organizations can streamline technology transfer and maintain operational resilience in the face of supply chain disruptions or regulatory changes. In addition, forging multi-stakeholder alliances across academia, contract research organizations, and in-region players will amplify R&D productivity and de-risk long-lead development projects.
Furthermore, decision-makers are advised to integrate sustainability and animal welfare imperatives into strategic roadmaps, leveraging enzyme-based feed enhancements and precision immunization to reduce environmental footprints. Proactive engagement with policymakers on evolving trade tariffs and compliance standards will ensure timely adaptation of sourcing and distribution models. Ultimately, a balanced approach that combines technological agility, collaborative networks, and regulatory foresight will position organizations to capitalize on emerging animal biotechnology opportunities.
Robust Research Methodology Combining Primary Insights, Secondary Data, and Qualitative Analysis to Illuminate Animal Biotechnology Market Trends
This research leverages a hybrid methodology that synthesizes primary insights from in-depth interviews with industry experts, regulatory authorities, and corporate strategists. These qualitative inputs are triangulated with secondary data drawn from peer-reviewed journals, conference proceedings, and public filings to validate emerging trends. Throughout the analysis, data integrity is maintained via cross-verification steps, ensuring that strategic conclusions reflect current market realities.
Complementing the data collection phase, the study employs structured analytical frameworks, including SWOT assessments, technology readiness evaluations, and value chain mapping. Regional market dynamics are interpreted through comparative analyses of policy environments, infrastructure maturity, and investment flows. This comprehensive approach underpins the credibility of the report’s findings and supports actionable insights tailored to decision-maker needs.
Final Reflections on the Evolution of Animal Biotechnology, Key Market Drivers, and Strategic Imperatives for Future Growth and Collaboration
In conclusion, animal biotechnology is at a pivotal juncture where scientific innovation, regulatory evolution, and shifting trade policies converge to reshape the global landscape. Stakeholders who embrace agile development practices, diversify supply chain footprints, and engage proactively with tariff developments will navigate these complexities more effectively. Simultaneously, collaborative models that bring together research institutions, commercial partners, and end-user communities will accelerate the translation of laboratory breakthroughs into field-ready solutions.
Looking ahead, the industry’s trajectory will be defined by its capacity to integrate advanced genomic tools, sustainable manufacturing processes, and data-driven decision support systems. Those who align product development with evolving welfare standards and environmental considerations will unlock new growth frontiers. By maintaining a forward-looking perspective and fostering strategic alliances, organizations can position themselves at the forefront of the next wave of animal biotechnology innovation.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Recombinant Proteins
Antibodies
Enzymes
Lipases
Phytases
Proteases
Growth Hormones
Vaccines
DNA Vaccines
Inactivated Vaccines
Live Attenuated Vaccines
Subunit Vaccines
Technology
Cell Culture
Avian Cell Culture
Insect Cell Culture
Mammalian Cell Culture
Genetic Engineering
Gene Editing
Gene Synthesis
Transgenic Technology
PCR And DNA Sequencing
Next-Generation Sequencing
PCR Kits
Sanger Sequencing
Application
Diagnostics
ELISA Kits
Lateral Flow Assays
PCR-Based Tests
Drug Discovery
Lead Optimization
Preclinical Testing
Target Identification
Feed Additives
Carbohydrases
Phytases
Proteases
End-User
Animal Farms
Contract Research Organizations
Pharmaceutical Companies
Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Zoetis Inc.
Merck & Co., Inc.
Elanco Animal Health Incorporated
Boehringer Ingelheim International GmbH
Ceva Santé Animale S.A.
Dechra Pharmaceuticals PLC
Vetoquinol S.A.
Phibro Animal Health Corporation
Virbac S.A.
IDEXX Laboratories, Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Overview of Animal Biotechnology Advancements and Market Dynamics Shaping the Future of Veterinary Health and Agriculture
Animal biotechnology represents a convergence of molecular science, genetic engineering, and veterinary research, delivering innovative solutions that improve animal health, productivity, and welfare. Over the past decade, breakthroughs in gene editing, cell culture platforms, and recombinant protein expression have redefined how the industry approaches diagnostics, therapeutics, and nutritional supplements for livestock, companion animals, and aquaculture. These advances have not only accelerated the development of safer and more effective vaccines but also enabled precise interventions in metabolic pathways to enhance growth performance and disease resistance.
In this context of rapid transformation, stakeholders face an unprecedented need for comprehensive market intelligence that illuminates technological progress, regulatory landscapes, and competitive strategies. As emerging players introduce next-generation sequencing and transgenic models into their R&D pipelines, established firms are expanding contract research and manufacturing collaborations to maintain leadership. This introduction lays the groundwork for a detailed exploration of the structural shifts, tariff influences, segmentation patterns, regional dynamics, and strategic imperatives that define the modern animal biotechnology ecosystem.
Major Shifts Propelling Animal Biotechnology from Gene Editing Breakthroughs to Integrated Diagnostic Solutions in Veterinary and Livestock Management
Over recent years, animal biotechnology has undergone radical transformation driven by converging scientific disciplines and evolving stakeholder priorities. Initially centered on recombinant protein production and conventional vaccine design, the landscape now embraces precision gene editing tools such as CRISPR, high-throughput cell culture systems, and integrated diagnostic assays. Consequently, developers are shifting from monolithic product pipelines toward modular platforms that accommodate rapid customization, accelerated timelines, and adaptive regulatory strategies.
Moreover, the sector has witnessed a surge in partnerships between academic research institutions and private enterprises, fostering knowledge exchange and de-risked development pathways. Simultaneously, digital convergence through data-driven decision support and remote monitoring technologies is redefining veterinary health management. These transformative shifts underscore the importance of agility, cross-disciplinary collaboration, and forward-looking business models to capitalize on opportunities in preventive care, therapeutic innovation, and feed additive optimization.
Assessing the 2025 United States Tariffs Impact on Global Animal Biotechnology Trade Flows, Supply Chains, and Research Collaborations
The introduction of elevated US tariffs in 2025 has altered the calculus for global trade in animal biotechnology inputs and finished products. Raw materials such as enzyme substrates and cell culture reagents are now subject to additional duties, prompting many manufacturers to reassess sourcing strategies and inventory management practices. As a direct consequence, supply chain resilience has become a central concern, with companies exploring regionalized production hubs and multi-tiered logistics networks to mitigate exposure to tariff fluctuations.
In parallel, research collaborations spanning cross-border academic and industrial partners are adapting contractual frameworks to reflect shifting cost structures. Licensing agreements, joint ventures, and technology transfer arrangements now account for potential duty adjustments, ensuring that development timelines remain intact despite the evolving trade environment. Ultimately, these dynamics are reshaping procurement, partnership, and pricing strategies across the animal biotechnology value chain.
Comprehensive Analysis of Product Type, Technology, Application, and End-User Segments Driving Animal Biotechnology Market Development
A granular look at product type segmentation reveals that recombinant proteins and vaccines form the backbone of innovation. Within recombinant proteins, antibodies, enzymes, and growth hormones serve distinct roles in diagnostics, biocatalysis, and metabolic regulation. Delving deeper, enzymes such as lipases, phytases, and proteases enable targeted feed additive solutions that enhance nutrient absorption, while vaccine categories ranging from DNA to live attenuated and subunit formats cater to tailored immunization strategies.
Turning to technology, cell culture methodologies span avian, insect, and mammalian cell lines to support scalable biomanufacturing. Genetic engineering encompasses gene editing, synthesis, and transgenic approaches that underpin advanced therapeutic development. PCR and DNA sequencing technologies, including next-generation platforms, specialized kits, and traditional Sanger workflows, provide the analytical backbone for pathogen detection and genomic characterization. Application segmentation highlights diagnostics, drug discovery, and feed additives, each supported by specialized assay formats, optimization protocols, and performance metrics. Finally, end users from animal farms to contract research organizations, pharmaceutical manufacturers, and research laboratories demand customizable solutions that align with operational scale, regulatory compliance, and cost-effectiveness.
Strategic Regional Dynamics Defining Growth Patterns and Opportunities in Americas, Europe, Middle East & Africa, and Asia-Pacific Animal Biotechnology Markets
In the Americas, robust R&D infrastructure, established commercial supply chains, and proactive regulatory agencies drive high-value innovation in animal biotechnology. Domestic producers benefit from local access to advanced bioprocessing facilities and a mature venture capital ecosystem, enabling iterative product refinement and rapid scale-up. Meanwhile, cross-border collaborations within North and South America expand market reach and foster capacity building in emerging economies.
Across Europe, the Middle East & Africa region, harmonized regulatory frameworks, public funding initiatives, and pan-regional research consortia support harmonized development pathways. European Union directives on animal welfare and product registration shape the competitive landscape, whereas Middle East and African markets exhibit growing livestock production and immunization uptake. In the Asia-Pacific, surging demand for protein through intensified livestock farming, coupled with government incentives for biotechnology manufacturing, has catalyzed rapid expansion. Local players are investing in cell culture facilities and genomic services, while multinational firms forge strategic alliances to navigate diverse regulatory regimes.
Leading Industry Participants Shaping Competitive Dynamics and Collaborative Innovations within the Global Animal Biotechnology Landscape
Leading companies in the animal biotechnology space are orchestrating dynamic partnerships to bolster their pipelines and expand market presence. Established biopharmaceutical firms are integrating genomic editing capabilities and contract research expertise, while specialized startups are advancing proprietary platforms for vaccine antigen discovery and enzyme engineering. These actors frequently engage in licensing agreements, joint development projects, and co-manufacturing arrangements to optimize resource allocation and accelerate commercialization timelines.
Strategic acquisitions have also become a hallmark of competitive positioning, with larger entities targeting niche players to augment their product portfolios or secure novel technology platforms. Simultaneously, cross-sector collaborations with feed additive producers, diagnostic assay developers, and digital monitoring providers are emerging to create end-to-end solutions. Through these maneuvers, key industry participants are not only consolidating capabilities but also fostering ecosystems that facilitate continuous innovation and sustainable growth.
Strategic Recommendations for Industry Leaders to Enhance Resilience, Foster Innovation, and Capitalize on Emerging Animal Biotechnology Trends
Industry leaders should prioritize investment in flexible manufacturing platforms that can pivot swiftly to new product candidates or capacity expansions. By adopting modular bioprocessing designs and cloud-enabled analytics, organizations can streamline technology transfer and maintain operational resilience in the face of supply chain disruptions or regulatory changes. In addition, forging multi-stakeholder alliances across academia, contract research organizations, and in-region players will amplify R&D productivity and de-risk long-lead development projects.
Furthermore, decision-makers are advised to integrate sustainability and animal welfare imperatives into strategic roadmaps, leveraging enzyme-based feed enhancements and precision immunization to reduce environmental footprints. Proactive engagement with policymakers on evolving trade tariffs and compliance standards will ensure timely adaptation of sourcing and distribution models. Ultimately, a balanced approach that combines technological agility, collaborative networks, and regulatory foresight will position organizations to capitalize on emerging animal biotechnology opportunities.
Robust Research Methodology Combining Primary Insights, Secondary Data, and Qualitative Analysis to Illuminate Animal Biotechnology Market Trends
This research leverages a hybrid methodology that synthesizes primary insights from in-depth interviews with industry experts, regulatory authorities, and corporate strategists. These qualitative inputs are triangulated with secondary data drawn from peer-reviewed journals, conference proceedings, and public filings to validate emerging trends. Throughout the analysis, data integrity is maintained via cross-verification steps, ensuring that strategic conclusions reflect current market realities.
Complementing the data collection phase, the study employs structured analytical frameworks, including SWOT assessments, technology readiness evaluations, and value chain mapping. Regional market dynamics are interpreted through comparative analyses of policy environments, infrastructure maturity, and investment flows. This comprehensive approach underpins the credibility of the report’s findings and supports actionable insights tailored to decision-maker needs.
Final Reflections on the Evolution of Animal Biotechnology, Key Market Drivers, and Strategic Imperatives for Future Growth and Collaboration
In conclusion, animal biotechnology is at a pivotal juncture where scientific innovation, regulatory evolution, and shifting trade policies converge to reshape the global landscape. Stakeholders who embrace agile development practices, diversify supply chain footprints, and engage proactively with tariff developments will navigate these complexities more effectively. Simultaneously, collaborative models that bring together research institutions, commercial partners, and end-user communities will accelerate the translation of laboratory breakthroughs into field-ready solutions.
Looking ahead, the industry’s trajectory will be defined by its capacity to integrate advanced genomic tools, sustainable manufacturing processes, and data-driven decision support systems. Those who align product development with evolving welfare standards and environmental considerations will unlock new growth frontiers. By maintaining a forward-looking perspective and fostering strategic alliances, organizations can position themselves at the forefront of the next wave of animal biotechnology innovation.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Recombinant Proteins
Antibodies
Enzymes
Lipases
Phytases
Proteases
Growth Hormones
Vaccines
DNA Vaccines
Inactivated Vaccines
Live Attenuated Vaccines
Subunit Vaccines
Technology
Cell Culture
Avian Cell Culture
Insect Cell Culture
Mammalian Cell Culture
Genetic Engineering
Gene Editing
Gene Synthesis
Transgenic Technology
PCR And DNA Sequencing
Next-Generation Sequencing
PCR Kits
Sanger Sequencing
Application
Diagnostics
ELISA Kits
Lateral Flow Assays
PCR-Based Tests
Drug Discovery
Lead Optimization
Preclinical Testing
Target Identification
Feed Additives
Carbohydrases
Phytases
Proteases
End-User
Animal Farms
Contract Research Organizations
Pharmaceutical Companies
Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Zoetis Inc.
Merck & Co., Inc.
Elanco Animal Health Incorporated
Boehringer Ingelheim International GmbH
Ceva Santé Animale S.A.
Dechra Pharmaceuticals PLC
Vetoquinol S.A.
Phibro Animal Health Corporation
Virbac S.A.
IDEXX Laboratories, Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of CRISPR/Cas9 gene editing to enhance disease resistance in poultry farming operations
- 5.2. Commercial scale adoption of cell cultured meat production to reduce environmental impact and meet consumer demand
- 5.3. Integration of artificial intelligence and genomics data for predictive health management in dairy cattle herds
- 5.4. Advances in microbiome modulation therapies to improve feed efficiency and disease resilience in swine
- 5.5. Deployment of recombinant vaccine platforms to control emerging zoonotic diseases in livestock industries
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Animal Biotechnology Market, by Product Type
- 8.1. Recombinant Proteins
- 8.1.1. Antibodies
- 8.1.2. Enzymes
- 8.1.2.1. Lipases
- 8.1.2.2. Phytases
- 8.1.2.3. Proteases
- 8.1.3. Growth Hormones
- 8.2. Vaccines
- 8.2.1. DNA Vaccines
- 8.2.2. Inactivated Vaccines
- 8.2.3. Live Attenuated Vaccines
- 8.2.4. Subunit Vaccines
- 9. Animal Biotechnology Market, by Technology
- 9.1. Cell Culture
- 9.1.1. Avian Cell Culture
- 9.1.2. Insect Cell Culture
- 9.1.3. Mammalian Cell Culture
- 9.2. Genetic Engineering
- 9.2.1. Gene Editing
- 9.2.2. Gene Synthesis
- 9.2.3. Transgenic Technology
- 9.3. PCR And DNA Sequencing
- 9.3.1. Next-Generation Sequencing
- 9.3.2. PCR Kits
- 9.3.3. Sanger Sequencing
- 10. Animal Biotechnology Market, by Application
- 10.1. Diagnostics
- 10.1.1. ELISA Kits
- 10.1.2. Lateral Flow Assays
- 10.1.3. PCR-Based Tests
- 10.2. Drug Discovery
- 10.2.1. Lead Optimization
- 10.2.2. Preclinical Testing
- 10.2.3. Target Identification
- 10.3. Feed Additives
- 10.3.1. Carbohydrases
- 10.3.2. Phytases
- 10.3.3. Proteases
- 11. Animal Biotechnology Market, by End-User
- 11.1. Animal Farms
- 11.2. Contract Research Organizations
- 11.3. Pharmaceutical Companies
- 11.4. Research Laboratories
- 12. Animal Biotechnology Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Animal Biotechnology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Animal Biotechnology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Zoetis Inc.
- 15.3.2. Merck & Co., Inc.
- 15.3.3. Elanco Animal Health Incorporated
- 15.3.4. Boehringer Ingelheim International GmbH
- 15.3.5. Ceva Santé Animale S.A.
- 15.3.6. Dechra Pharmaceuticals PLC
- 15.3.7. Vetoquinol S.A.
- 15.3.8. Phibro Animal Health Corporation
- 15.3.9. Virbac S.A.
- 15.3.10. IDEXX Laboratories, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
